The short answer
Retatrutide is developed by Eli Lilly and Company under the internal code LY3437943. No licensed retatrutide product exists anywhere, so there is no manufacturer of an approved medicine, only a sponsor running clinical trials.
Key facts
- Developer
- Eli Lilly and Company
- Internal code
- LY3437943
- Other Lilly incretins
- Tirzepatide, orforglipron, dulaglutide
- Licensed product
- None
- Trial sponsor
- Eli Lilly
- Signalled filing
- FDA, Q1 2027
The LY prefix
LY is Eli Lilly's development prefix, the same convention as NNC for Novo Nordisk, BI for Boehringer Ingelheim and CJC for ConjuChem. Seeing LY3437943 in a paper identifies the sponsor immediately, and this is useful to know because Lilly's incretin portfolio is unusually crowded: tirzepatide is LY3298176 and orforglipron is LY3502970.
Why the portfolio matters for reading the data
Lilly develops retatrutide, tirzepatide and orforglipron simultaneously, and they compete with each other. TRIUMPH-5 compares retatrutide against tirzepatide. A company running a head-to-head between two of its own compounds is an informative design, because there is no incentive to disadvantage either.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The confusion this creates
Three Lilly incretins with similar codes is a recipe for mixed-up citations, and this library found exactly that: a PubChem record for tirzepatide cited as retatrutide, and a trial registration for orforglipron's ATTAIN-1 labelled as retatrutide's TRIUMPH-1. Both were plausible-looking and both were wrong. Checking the compound named in a record, not just its number, is the defence.
There is no manufacturer of a product
Because no retatrutide product is licensed anywhere, there is no approved manufacturer. Material described as retatrutide and sold outside clinical trials does not originate from Lilly and has no connection to the compound in the TRIUMPH programme beyond the sequence it claims to be.
What that means here
Research material supplied under this name is synthesised by peptide manufacturers, characterised by a certificate of analysis, and supplied for laboratory use. It is not the trial compound, not a licensed medicine, and not connected to Eli Lilly.
Frequently asked questions
Who develops retatrutide?
Eli Lilly and Company, under the internal code LY3437943.
Is there an approved retatrutide product?
No. It is investigational everywhere, so there is no licensed manufacturer, only a trial sponsor.
Is research material made by Lilly?
No. It is synthesised by peptide manufacturers and supplied for laboratory use, with no connection to the trial programme.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- RefTRIUMPH-1 topline results: Eli Lillyinvestor.lilly.com
- TrialClinicalTrials.gov: TRIUMPH-5 (NCT06662383)clinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Retatrutide Half-Life: Where It Comes FromThe C20 diacid binds albumin reversibly, supporting once-weekly trial dosing. Why chain length sets duration across the whole incretin family.
- Retatrutide Chemical Identity: What Can Actually Be VerifiedRetatrutide has no findable PubChem record. What that means for its reported CAS and molecular weight, and why one widely cited identifier is tirzepatide's.
- How the Incretin Field Got HereExenatide from lizard venom, liraglutide's fatty acid, semaglutide's weekly dosing, then multi-agonism. Each generation solved the previous one's limit.
- Retatrutide Storage and StabilityA lipidated 39-mer is more surface-active than most peptides. Why foaming matters more here, and what the fatty acid changes about handling.
- Retatrutide Molecular Weight4,731.33 Da is the figure everyone quotes. It comes from supplier sources rather than a primary database, and at least one reference gives a different formula.